Atlas Trials

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Clinical trial NCT03740724 · TERMINATED

Trial details

NCT number
NCT03740724
Sponsor
Castle Creek Biosciences, LLC.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
MorpheaScleroderma, LocalizedScleroderma
Start date
2019-12-18
Primary completion
2020-09-23
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.